202 related articles for article (PubMed ID: 23106055)
1. Imaging beyond the striatonigral dopaminergic system in Parkinson's disease.
Giza E; Gotzamani-Psarrakou A; Bostantjopoulou S
Hell J Nucl Med; 2012; 15(3):224-32. PubMed ID: 23106055
[TBL] [Abstract][Full Text] [Related]
2. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
Thobois S; Jahanshahi M; Pinto S; Frackowiak R; Limousin-Dowsey P
Neuroimage; 2004 Sep; 23(1):1-16. PubMed ID: 15325346
[TBL] [Abstract][Full Text] [Related]
3. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease.
Chiaravalloti A; Stefani A; Di Biagio D; Pierantozzi M; Tavolozza M; Di Pietro B; Stanzione P; Schillaci O
Ann Nucl Med; 2013 Jun; 27(5):444-51. PubMed ID: 23443954
[TBL] [Abstract][Full Text] [Related]
4. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.
Kuriakose R; Stoessl AJ
Prog Brain Res; 2010; 184():177-92. PubMed ID: 20887875
[TBL] [Abstract][Full Text] [Related]
5. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
Piccini P; Turjanski N; Brooks DJ
J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic function and progression of Parkinson's disease: PET findings.
Biju G; de la Fuente-Fernández R
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S38-40. PubMed ID: 20123555
[TBL] [Abstract][Full Text] [Related]
7. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
8. [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study.
Kuten J; Linevitz A; Lerman H; Freedman N; Kestenbaum M; Shiner T; Giladi N; Even-Sapir E
J Integr Neurosci; 2020 Sep; 19(3):489-494. PubMed ID: 33070528
[TBL] [Abstract][Full Text] [Related]
9. The role of SPECT imaging of the dopaminergic system in translational research on Parkinson's disease.
Suwijn SR; de Bruin K; de Bie RM; Booij J
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S184-6. PubMed ID: 24262177
[TBL] [Abstract][Full Text] [Related]
10. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.
Frey KA
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):715-7. PubMed ID: 11976814
[No Abstract] [Full Text] [Related]
11. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.
Caminiti SP; Presotto L; Baroncini D; Garibotto V; Moresco RM; Gianolli L; Volonté MA; Antonini A; Perani D
Neuroimage Clin; 2017; 14():734-740. PubMed ID: 28409113
[TBL] [Abstract][Full Text] [Related]
12. Nigrostriatal dopaminergic function in subjects with isolated action tremor.
Coria F; Gimenez-Garcia M; Samaranch L; Mora FJ; Sampol-Bas C; Pastor P
Parkinsonism Relat Disord; 2012 Jan; 18(1):49-53. PubMed ID: 21917500
[TBL] [Abstract][Full Text] [Related]
13. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism.
Booij J; Tissingh G; Winogrodzka A; van Royen EA
Eur J Nucl Med; 1999 Feb; 26(2):171-82. PubMed ID: 9933352
[TBL] [Abstract][Full Text] [Related]
14. Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.
Booij J; Berendse HW
J Neurol Sci; 2011 Nov; 310(1-2):40-3. PubMed ID: 21840542
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease.
Muellner J; Gharrad I; Habert MO; Kas A; Martini JB; Cormier-Dequaire F; Tahiri K; Vidailhet M; Meier N; Brice A; Schuepbach M; Mallet A; Hartmann A; Corvol JC
Parkinsonism Relat Disord; 2015 May; 21(5):471-6. PubMed ID: 25753458
[TBL] [Abstract][Full Text] [Related]
16. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
Cordes M; Poewe W
Nervenarzt; 1994 Oct; 65(10):696-9. PubMed ID: 7808568
[TBL] [Abstract][Full Text] [Related]
17. Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.
Bohnen NI; Müller ML; Zarzhevsky N; Koeppe RA; Bogan CW; Kilbourn MR; Frey KA; Albin RL
Brain; 2011 Aug; 134(Pt 8):2358-65. PubMed ID: 21653540
[TBL] [Abstract][Full Text] [Related]
18. [Molecular imaging in Parkinson's disease].
Arahata Y; Kato T; Ito K
Nihon Rinsho; 2007 Feb; 65(2):327-31. PubMed ID: 17302279
[TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor mapping with PET imaging in Parkinson's disease.
Niccolini F; Su P; Politis M
J Neurol; 2014 Dec; 261(12):2251-63. PubMed ID: 24627109
[TBL] [Abstract][Full Text] [Related]
20. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
